Product & regulatory approvals

Gates that opened: regulatory and product approvals — drug approvals, licences, clearances — disclosed to the exchanges inside the window. The approval filing is linked on every row.

CompanyWhy it’s here — the filingReaction 1d / 1w / 1mPriceMcapP/EROCERev YoY
Iirm Holdings IndiaConsulting ServicesSubsidiary gets IRDAI registration as Corporate Agent19 Aug 2026Regulatory Product Approvalpending₹132900 Cr37.0vs 7.514.4%+15.3%
Permanent MagnetsOther Electrical EquipmentSubsidiary Quantum Magnetics gets ECMS approval for Neodymium magnets18 Aug 2026Regulatory Product Approvalpending₹884760 Cr50.4vs 25.99.3%+47.0%
WanburyPharmaceuticalsWanbury gets EDQM nod for Rivaroxaban API, USFDA DMF clearances13 Aug 2026Regulatory Product Approval×2-2.0% ₹267876 Cr12.9vs 28.5+22.3%
Arrow GreentechPackagingArrow Greentech granted patent for Dual Colour Shift Security Film12 Aug 2026Regulatory Product Approval+5.7% ₹6921,044 Cr25.2vs 18.627.2%-31.6%
Man InfraResidential Commercial ProjectsMICL Group gets IOA for Bandra luxury project with 1000+ crore GDV10 Aug 2026Regulatory Product Approval-2.2% -3.3% ₹1104,440 Cr24.8vs 22.311.4%-2.2%
GeeOther Electrical EquipmentGEE Limited gets NPCIL vendor approval for nuclear power supply chain6 Aug 2026Regulatory Product Approval+10.6% +20.3% ₹135700 Cr27.7vs 25.97.8%+27.5%
Steel City SecuritiesStockbroking & AlliedSteel City Securities gets Market Maker approval from NSE and BSE4 Aug 2026Regulatory Product Approval-2.5% -3.9% ₹81.49123 Cr8.5vs 15.513.8%+7.4%
Ashiana HousingResidential Commercial ProjectsJuly 2026 ops: Bookings at 501.76 Cr, OCs received for Gurugram projects1 Aug 2026Regulatory Product Approval-1.0% -3.8% ₹3643,656 Cr22.3vs 22.313.1%+95.0%
Fischer Medical Venture LMedical Equipment & SuppliesFischer Medical Ventures Gets CDSCO Import Approval for Spincare System30 Jul 2026Regulatory Product Approval+7.5% +9.6% ₹39.152,562 Cr103.0vs 18.911.3%+13.2%
India PesticidesPesticides & AgrochemicalsIndia Pesticides gets fungicide approval in Morocco29 Jul 2026Regulatory Product Approval+0.6% -6.0% ₹1391,596 Cr15.0vs 24.915.5%-52.9%
Meghna Infracon Infra LResidential, Commercial ProjectsMeghna Infracon delivers Riviera project in Goregaon in 16 months28 Jul 2026Regulatory Product Approval-0.4% -3.0% ₹7121,547 Cr228.2vs 16.133.9%+52.5%
Supreme Holdin N Hosp I LResidential Commercial ProjectsCIDCO approves 3 extra floors at Belmac Infinity, project revised from G+10 to G+1327 Jul 2026Regulatory Product Approval+0.9% +2.0% ₹39.21152 Cr980.3vs 22.30.1%+2243.6%
Goodluck IndiaIron & Steel ProductsSubsidiary Gets Defence Quality Certification for Artillery Shells27 Jul 2026Regulatory Product Approval+0.2% +0.5% ₹1,4364,771 Cr23.1vs 17.213.5%+9.8%
Rhetan TMTIron & Steel ProductsBIS Certification for Premium TMT Grades Opens Government and PSU Market27 Jul 2026Regulatory Product Approval+4.1% +13.9% ₹22.021,755 Cr78.6vs 17.29.7%+78.5%
Indo Tech TransformINDOTECHEnters 400 kV transformer segment with NTPC approval and initial order24 Jul 2026Regulatory Product Approval+1.9% +5.6% ₹3,7343,966 Cr40.632.4%+30.7%
Jeevan Scientific Technology LHealthcare Research, Analytics & TechnologyUSFDA inspection closed with zero observations at Hyderabad facility24 Jul 2026Regulatory Product Approval+5.8% +8.0% ₹74147 Cr16.52.4%+111.6%
Kwality Pharmaceuticals LPharmaceuticalsKwality Pharma gets CDSCO nod for Pembroluzimab preclinical batches24 Jul 2026Regulatory Product Approval+1.2% -3.0% ₹3,6353,771 Cr56.0vs 28.524.4%+35.8%
Bondada EngineeringTelecom - InfrastructureCEA approves 300 MW solar project energization at Khavda for NLC India23 Jul 2026Regulatory Product Approval-1.1% -2.7% ₹2973,309 Cr11.8vs 12.737.2%+90.2%
How this list is built

A company appears when an NSE/BSE filing inside the last 30 days carries one of these classifier signals (minimum importance: Medium): Regulatory Product Approval. Each row shows the latest qualifying filing; the reaction columns are the stock’s measured move 1 day, 1 week and 1 month after that filing.

MarketPing publishes facts, filings and measured history only — nothing on this page is investment advice, a recommendation or a rating.